Ferumoxytol (Frx) is an MRI contrast media with no toxicity concerning gadolinium-based contrast in ptns with progressive kidney disease.
Frx is composed of ultra-small paramagnetic Fe oxide embedded in a CHO coating & got the approval of the US FDA as a . It is cleared from the circulation via the reticuloendothelial system macrophages of the liver, spleen, & bone marrow. Considering its iron content, Frx can be used as a contrast medium for the MRI testing ("off label"). Frx has prolonged ½ -life (15 h.) that permits the imaging of both venous & arterial vasculature with no need for bolus timing, with excellent imaging results for peripheral & central veino-arterial system.